Also, Kaplan-Meier survival analysis in patients with PDL1 expression < 49% diagnosed with adenocarcinoma and negative KRAS mutation were found with median overall survival of 39 months when compared to patients with positive KRAS mutation (28 months, p < 0.05), (Figure 4b). This evidence concerns the gene KRAS and adenocarcinoma.